ATE420097T1 - Substituierte sapogenine und ihre verwendung - Google Patents

Substituierte sapogenine und ihre verwendung

Info

Publication number
ATE420097T1
ATE420097T1 AT01900185T AT01900185T ATE420097T1 AT E420097 T1 ATE420097 T1 AT E420097T1 AT 01900185 T AT01900185 T AT 01900185T AT 01900185 T AT01900185 T AT 01900185T AT E420097 T1 ATE420097 T1 AT E420097T1
Authority
AT
Austria
Prior art keywords
substituted sapogenins
sapogenins
treatment
substituted
disclosed
Prior art date
Application number
AT01900185T
Other languages
English (en)
Inventor
Paul Barraclough
Jim Hanson
Phil Gunning
Daryl Rees
Zongqin Xia
Yaer Hu
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Application granted granted Critical
Publication of ATE420097T1 publication Critical patent/ATE420097T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Catalysts (AREA)
AT01900185T 2000-01-06 2001-01-08 Substituierte sapogenine und ihre verwendung ATE420097T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0000228.7A GB0000228D0 (en) 2000-01-06 2000-01-06 Fluoro substituted sapogenins and their use

Publications (1)

Publication Number Publication Date
ATE420097T1 true ATE420097T1 (de) 2009-01-15

Family

ID=9883260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01900185T ATE420097T1 (de) 2000-01-06 2001-01-08 Substituierte sapogenine und ihre verwendung

Country Status (15)

Country Link
US (3) US20030158161A1 (de)
EP (1) EP1246835B9 (de)
JP (1) JP2003519624A (de)
CN (1) CN1215080C (de)
AT (1) ATE420097T1 (de)
AU (1) AU2386201A (de)
BR (1) BR0107691A (de)
CA (1) CA2395100C (de)
DE (1) DE60137307D1 (de)
ES (1) ES2323671T3 (de)
GB (1) GB0000228D0 (de)
HK (1) HK1046912B (de)
MX (1) MXPA02006720A (de)
PT (1) PT1246835E (de)
WO (1) WO2001049703A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
PE20040306A1 (es) * 2002-03-27 2004-05-29 Phytopharm Plc Metodos terapeuticos de sapogeninas y sus derivados
KR20080031062A (ko) * 2002-03-27 2008-04-07 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 용도
MXPA04009321A (es) * 2002-03-27 2005-01-25 Phytopharm Plc Metodos y usos terapeuticos de sapogeninas y sus derivados.
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
EP1558627B1 (de) 2002-10-28 2010-03-03 Phytopharm Plc Stereospezifische reduktion von sapogen-3-onen
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CN103189056A (zh) 2010-07-20 2013-07-03 植物药物公共有限公司 L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗
RU2665571C2 (ru) 2011-09-08 2018-08-31 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их применения
WO2013149580A1 (en) 2012-04-03 2013-10-10 Chiming Che Timosaponin compounds
RS58166B1 (sr) 2013-03-13 2019-03-29 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN106905407B (zh) * 2015-01-27 2019-08-13 华东理工大学 知母皂苷元结构修饰的衍生物、其药物组合物及其应用
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RU2744267C2 (ru) 2015-07-06 2021-03-04 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
CN113501855A (zh) 2015-07-06 2021-10-15 萨奇治疗股份有限公司 氧甾醇及其使用方法
KR101777920B1 (ko) * 2015-07-27 2017-09-14 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 포함하는 아밀로이드 플라크 제거용 조성물
PT3436022T (pt) 2016-04-01 2022-07-04 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
AU2017337121B2 (en) 2016-09-30 2022-01-27 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as NMDA modulators
EP4105223A1 (de) 2016-10-18 2022-12-21 Sage Therapeutics, Inc. Oxysterole und verfahren zur verwendung davon
IL266093B2 (en) 2016-10-18 2024-02-01 Sage Therapeutics Inc Oxysterols and methods of using them
CN108117580A (zh) * 2016-11-30 2018-06-05 沈阳药科大学 菝葜皂苷元衍生物及其制备方法和用途
CN108264535A (zh) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用
CN109206472A (zh) * 2018-09-27 2019-01-15 华东理工大学 薯蓣皂苷元衍生物、其药物组合物及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695287A (en) * 1952-01-08 1954-11-23 Merck & Co Inc Isoallospirostane derivatives and process
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
ES359406A1 (es) * 1967-10-23 1970-06-01 Erba Carlo Spa Procedimiento para la preparacion de nuevos derivados de (25r)-3 beta-amino-5alfa, 22alfa-espirostano.
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) * 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) * 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) * 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
JPS5855500A (ja) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
SG50585A1 (en) * 1990-01-18 1998-07-20 Cura Nominees Pty Ltd Glycoalkaloids
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
AU4226593A (en) * 1992-06-26 1994-01-24 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
EP0696292A1 (de) * 1993-04-28 1996-02-14 Pfizer Inc. Spirostanyl-glycosid-kristall-monohydrat
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
EP0737202A1 (de) * 1993-12-28 1996-10-16 Pfizer Inc. Hypocholesterolemische mittel
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
JPH09510735A (ja) * 1994-08-30 1997-10-28 フアイザー・インコーポレイテツド スピロスタニルグリコシド性結晶
MX9702175A (es) * 1994-09-20 1997-06-28 Pfizer Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
AU7145996A (en) * 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
US5726179A (en) * 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
EP0923376B1 (de) * 1996-05-09 2004-11-03 Amrad Operations Pty.,Ltd. Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
US5804239A (en) * 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US20030118673A1 (en) * 1998-03-26 2003-06-26 Zongqin Xia Smilagenin and anzurogenin-D for the treatment of alzheimer's disease
PL195897B1 (pl) * 1998-03-26 2007-11-30 Phytopharm Plc Zastosowanie smilageniny
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US6687613B2 (en) * 2001-05-31 2004-02-03 Alpine Electronics, Inc. Display method and apparatus of navigation system
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
EP1558627B1 (de) * 2002-10-28 2010-03-03 Phytopharm Plc Stereospezifische reduktion von sapogen-3-onen

Also Published As

Publication number Publication date
HK1046912A1 (en) 2003-01-30
JP2003519624A (ja) 2003-06-24
US20030158161A1 (en) 2003-08-21
GB0000228D0 (en) 2000-03-01
CA2395100C (en) 2010-12-21
US20080207576A1 (en) 2008-08-28
CA2395100A1 (en) 2001-07-12
PT1246835E (pt) 2009-04-15
EP1246835B1 (de) 2009-01-07
EP1246835A2 (de) 2002-10-09
US20100087411A1 (en) 2010-04-08
WO2001049703A3 (en) 2002-02-21
HK1046912B (zh) 2009-07-31
CN1215080C (zh) 2005-08-17
ES2323671T3 (es) 2009-07-23
DE60137307D1 (de) 2009-02-26
EP1246835B9 (de) 2010-02-17
BR0107691A (pt) 2005-03-22
AU2386201A (en) 2001-07-16
WO2001049703A2 (en) 2001-07-12
CN1452630A (zh) 2003-10-29
MXPA02006720A (es) 2002-09-30

Similar Documents

Publication Publication Date Title
DE60137307D1 (de) Substituierte sapogenine und ihre verwendung
ATE325808T1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE60238576D1 (de) Zusammensetzung zur Herstellung von Elektroden und Elektroden
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE314057T1 (de) Smilagenin und anzurogenin-d zur behandlung der alzheimerischen krankheit
NO20034056D0 (no) Proliferative sykdommer
ATE424211T1 (de) Therapeutische verwendung von sapogeninen
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE325789T1 (de) Aminocyclohexylether-verbindungen und deren verwendung
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
CA2385410A1 (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
GB9923078D0 (en) Sapogenin derivatives and their use
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
NO20060420L (no) 2-aminobenzoylderivater
TR200200278T2 (tr) Kalsilitik bileşimler
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE50113300D1 (de) Verwendung von erythropoietin sowie dessen derivate zur behandlung von schizophrenie und verwandten psychosen
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1246835

Country of ref document: EP